Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
OBJECTIVE
Somatostatin analogues are able to control symptoms and to detect tumour localisation in gastro-entero-pancreatic endocrine tumour patients. Few studies have evaluated the efficacy of somatostatin analogues in controlling tumoural growth during long-term treatment and, generally, a low efficacy has been reported in studies using multiple daily octreotide dosages. In the present study a single daily dose of octreotide (500 micrograms) for 1 year was used in the treatment of 10 patients with progressive gastro-entero-pancreatic metastatic tumour.


METHODS
Ten consecutive patients (3 females, 7 males age range 40-62 years) were studied of whom 4 had Zollinger-Ellison syndrome (2 with MEN-1), 3 had a carcinoid syndrome, and 3 had a non-functional neuro-endocrine tumour. All patients, 6-12 months before octreotide treatment, showed tumour progression. In all patients, somatostatin receptor status was assessed by Somatostatin Receptor Scintigraphy and tumoural lesions by Magnetic Resonance Imaging. Appropriate tumoural markers were also evaluated.


RESULTS
At the three-month control, two patients (non-functional) showed an aggressive progression of tumoural growth despite treatment and were excluded from the study. One patient was lost during follow-up. Of the 7 remaining patients, imaging evaluation studies revealed, after 1 year of treatment, stable disease in 6 patients, whereas a partial tumoural response was observed in one patient (gastrinoma). Biochemical tumoural markers decreased with respect to basal values of 53-78% in these seven patients at the end of therapy.


CONCLUSIONS
These results suggest that one year of octreotide in a single daily dose (500 micrograms) is effective in the long-term stabilization of tumoural progression in metastatic gastro-entero-pancreatic tumour patients.
Angeletti
S
S
Dept. of Digestive Diseases, Cellular Biotechnology and Haematology, University La Sapienza Roma, Italy.
Corleto
V D
VD
Schillaci
O
O
Moretti
A
A
Panzuto
F
F
Annibale
B
B
Delle Fave
G
G
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015408:Gastrinoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D008207:Lymphatic Metastasis; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D017481:Receptors, Somatostatin / Q000378:metabolism; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D017481:Receptors, Somatostatin; D015282:Octreotide